NCT02128906 2026-04-16
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
University of Pittsburgh
Phase 2 Recruiting
Clinical Trials
19 trialsNCT07419464 2026-04-09
5-Fluorouracil Response and Optimization STudy (The FROST Trial)
Washington University School of Medicine
Phase 2 Not yet recruiting
NCT01647477 2026-03-13
DEREDIA
Centre Oscar Lambret
Phase NA Terminated
NCT03656133 2026-02-20
Use of a Proliferation Saturation Index to Determine Personalized Radiotherapy for HPV + Oropharyngeal Cancers
H. Lee Moffitt Cancer Center and Research Institute
Phase NA Completed
NCT04368702 2026-02-09
CONFIRM
Brigham and Women's Hospital
Phase NA Recruiting
NCT07326358 2026-01-08
AI System for Anatomic Recognition & Lesion Detection in Nasopharyngolaryngoscopy: A Prospective Study
Ruijin Hospital
Recruiting
NCT00576134 2025-12-22
The Objective is to Respond to Patients' Needs in the Field of Larynx Replacement
University Hospital, Strasbourg, France
Phase 1 Completed
NCT07287865 2025-12-17
TL&TPL
Fondazione IRCCS Policlinico San Matteo di Pavia
Active not recruiting
NCT06080503 2025-11-26
G-FORCE
University of Texas Southwestern Medical Center
Phase NA Recruiting
NCT02586207 2025-10-07
Pembrolizumab in Combination With CRT for LA-SCCHN
Sanford Health
Phase 1 Completed
NCT06819228 2025-10-03
Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer
Vanderbilt-Ingram Cancer Center
Phase EARLY_PHASE1 Recruiting
NCT06915454 2025-10-03
High-Resolution PET-CT Imaging for Surgical Margin Visualization
Vanderbilt-Ingram Cancer Center
Phase NA Recruiting
NCT01644786 2025-10-02
The Head and Neck Tumor Biobank
Maastricht Radiation Oncology
Completed
NCT03340896 2025-09-02
SALTORL
Groupe Oncologie Radiotherapie Tete et Cou
Phase 3 Active not recruiting
NCT06078527 2025-07-23
Assessment of Laryngopharyngeal Sensation: Cancer Survivor Cohort
University of California, San Francisco
Phase NA Not yet recruiting
NCT03529422 2025-07-20
Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN
UNC Lineberger Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT03854032 2025-06-06
Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck
Thomas Jefferson University
Phase 2 Active not recruiting
NCT03109873 2025-04-30
Metformin Hydrochloride in Affecting Cytokines and Exosomes in Patients With Head and Neck Cancer
Thomas Jefferson University
Phase EARLY_PHASE1 Completed
NCT03162731 2025-04-29
Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage III-IVB Head and Neck Cancer
Thomas Jefferson University
Phase EARLY_PHASE1 Completed